Radient Technologies Inc V.RTI.H

Alternate Symbol(s): RDDTF

Radient Technologies Inc. is a science-based company. The Company is a commercial manufacturer of cannabinoid-based formulations, ingredients, and products. The principal activities of the Company and its subsidiaries are engaged in research, development, and commercialization of an efficient and environmentally responsible technology for the extraction, isolation, and purification of soluble products from a range of materials using microwave technology and a customized hydrocarbon extraction platform. The Company is focused on the formulation, manufacturing and launching of value-added cannabis products. It utilizes a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant. It develops specialty products and ingredients that contain a range of cannabinoid and terpene profiles.

TSXV:RTI.H - Post by User

Radient Technologies Inc

Bullboard Posts

Comment by rbm0524on Aug 24, 2017 2:06pm

159 Views

Post# 26618003

RE:Scientus Pharma

Good question. Note that their process is "patent pending" whereas Radient's patent is secured and in place. My understanding is Radient management is well aware of Scientus and investigating their process. Scientus likely infringing on Radient's patent so they are dead in the water.

BiggLebowski wrote: Anyone have any thoughts about this quote from a recent Aphria news release. Is this a competing technology or could RTI possibly be working with Scientus Pharma?

"Coming on the heels of the two companies completing a major wholesale supply agreement in June, this sizable investment serves to validate the Scientus Pharma business model to be the leader in extractions, formulations and provider of best of breed derivative medical cannabinoid based products. It also significantly expands our existing partnership, allowing Scientus Pharma to complete implementation of its patent pending commercial scale microwave extraction platform, an important step toward creating an active pharmaceutical ingredient that can be subsequently formulated into a range of effective dosing forms, and to execute the commercial launch of its first differentiated product."